Different effects of α-human atrial natriuretic peptide and nitroglycerin on cardiac dimensions in humans

Tsutomu Imaizumi, Akira Takeshita, Megumu Yoshida, Satoshi Suzuki, Shin ichi Ando, Yoshitaka Hirooka, Motoomi Nakamura

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


This study aimed to examine whether α-human atrial natriuretic peptide (α-hANP) alters cardiac dimensions in humans. Left atrial (LA) and left ventricular diastolic (LV) diameters were measured by echocardiography at control and with lower body negative pressure (LBNP) at -10 and -20 mmHg during intravenous (IV) infusion of saline or α-hANP at a dose of 0.03-0.04 μg/kg per minute (n=8). Studies were also done during IV infusion of saline or nitroglycerin (NG) at a dose of 10-15 μg/kg per minute in another group of subjects (n=6). LBNP decreased central venous pressure (CVP) and the LA and LV diameter. α-hANP lowered CVP at rest and with LBNP at -10 and -20 mmHg compared with corresponding values during saline infusion; NG produced comparable decreases in CVP, which suggests that decreases in venous return caused by the two drugs were similar. However, NG decreased, but α-hANP did not alter the LA and LV diameter at rest or with LBNP. In another group of subjects (n=4), we observed that α-hANP caused comparable decreases in CVP and pulmonary capillary wedge pressure. These data suggest that ANP may dilate the cardiac chambers in humans.

Original languageEnglish
Pages (from-to)87-92
Number of pages6
JournalHeart and Vessels
Issue number2
Publication statusPublished - Jun 1990
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Different effects of α-human atrial natriuretic peptide and nitroglycerin on cardiac dimensions in humans'. Together they form a unique fingerprint.

Cite this